BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

904 related articles for article (PubMed ID: 27012957)

  • 21. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
    Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
    Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
    [No Abstract]   [Full Text] [Related]  

  • 22. Blockade of deubiquitylating enzyme Rpn11 triggers apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
    Song Y; Li S; Ray A; Das DS; Qi J; Samur MK; Tai YT; Munshi N; Carrasco RD; Chauhan D; Anderson KC
    Oncogene; 2017 Oct; 36(40):5631-5638. PubMed ID: 28581522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.
    Das DS; Das A; Ray A; Song Y; Samur MK; Munshi NC; Chauhan D; Anderson KC
    Clin Cancer Res; 2017 Aug; 23(15):4280-4289. PubMed ID: 28270494
    [No Abstract]   [Full Text] [Related]  

  • 24. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma.
    Kuhn DJ; Chen Q; Voorhees PM; Strader JS; Shenk KD; Sun CM; Demo SD; Bennett MK; van Leeuwen FW; Chanan-Khan AA; Orlowski RZ
    Blood; 2007 Nov; 110(9):3281-90. PubMed ID: 17591945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
    Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
    Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. VR23: A Quinoline-Sulfonyl Hybrid Proteasome Inhibitor That Selectively Kills Cancer via Cyclin E-Mediated Centrosome Amplification.
    Pundir S; Vu HY; Solomon VR; McClure R; Lee H
    Cancer Res; 2015 Oct; 75(19):4164-75. PubMed ID: 26238784
    [TBL] [Abstract][Full Text] [Related]  

  • 27.
    Zhou H; Lei M; Wang W; Guo M; Wang J; Zhang H; Qiao L; Feng H; Liu Z; Chen L; Hou J; Wang X; Gu C; Zhao B; Izumchenko E; Yang Y; Zhu Y
    Aging (Albany NY); 2020 Nov; 12(22):22949-22974. PubMed ID: 33203800
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Exposure-safety-efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study.
    Gupta N; Labotka R; Liu G; Hui AM; Venkatakrishnan K
    Invest New Drugs; 2016 Jun; 34(3):338-46. PubMed ID: 27039387
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
    Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
    Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ixazomib: First Global Approval.
    Shirley M
    Drugs; 2016 Mar; 76(3):405-11. PubMed ID: 26846321
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The proteasome and proteasome inhibitors in multiple myeloma.
    Gandolfi S; Laubach JP; Hideshima T; Chauhan D; Anderson KC; Richardson PG
    Cancer Metastasis Rev; 2017 Dec; 36(4):561-584. PubMed ID: 29196868
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Syrbactin Structural Analog TIR-199 Blocks Proteasome Activity and Induces Tumor Cell Death.
    Bachmann AS; Opoku-Ansah J; Ibarra-Rivera TR; Yco LP; Ambadi S; Roberts CC; Chang CE; Pirrung MC
    J Biol Chem; 2016 Apr; 291(16):8350-62. PubMed ID: 26907687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of ixazomib for the treatment of multiple myeloma.
    Bonnet A; Moreau P
    Expert Opin Drug Saf; 2017 Aug; 16(8):973-980. PubMed ID: 28661711
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma.
    Chauhan D; Singh AV; Ciccarelli B; Richardson PG; Palladino MA; Anderson KC
    Blood; 2010 Jan; 115(4):834-45. PubMed ID: 19965674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma.
    Rychak E; Mendy D; Shi T; Ning Y; Leisten J; Lu L; Miller K; Narla RK; Orlowski RZ; Raymon HK; Bjorklund CC; Thakurta A; Gandhi AK; Cathers BE; Chopra R; Daniel TO; Lopez-Girona A
    Br J Haematol; 2016 Mar; 172(6):889-901. PubMed ID: 26914976
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
    Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
    Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
    Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
    Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib.
    Malek E; Driscoll JJ
    Oncotarget; 2016 Jun; 7(25):38523-38538. PubMed ID: 27229530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.
    Hasinoff BB; Patel D
    Cardiovasc Toxicol; 2018 Dec; 18(6):557-568. PubMed ID: 29951728
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellular effect and efficacy of carfilzomib depends on cellular net concentration gradient.
    Schäfer J; Welti L; Seckinger A; Burhenne J; Theile D; Weiss J
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):71-79. PubMed ID: 28500557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.